Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 07'th Jan 2025
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
01:36pm, Wednesday, 18'th Dec 2024
Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The g
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
01:23pm, Wednesday, 18'th Dec 2024
Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:42am, Wednesday, 18'th Dec 2024
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday.
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
07:30am, Wednesday, 18'th Dec 2024
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock wa
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, Dece
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Friday, 15'th Nov 2024
Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
10:01am, Thursday, 14'th Nov 2024
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases
Corvus Pharmaceuticals: The Market Likes The Story
01:18pm, Wednesday, 13'th Nov 2024
Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates with
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
12:02am, Wednesday, 13'th Nov 2024
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richar
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
04:01pm, Tuesday, 12'th Nov 2024
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 C
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract Data presented in an oral session at the Society for Immun
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
04:02pm, Tuesday, 05'th Nov 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
11:51am, Wednesday, 11'th Sep 2024
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
